CACI Int'l Wins Prime Position on Multiple-Award Contract

Loading...
Loading...
CACI International Inc
CACI
announced today that it has been awarded a prime position on the Engineering-Technical and Logistics Domains of the Omnibus Program Engineering and Technical Support (OPETS) contract. CACI will support development and fielding of chemical and biological defense materiel for the Department of Defense (DoD) Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD). With a ceiling value of approximately $40 million for each of the two domains, the five-year (three-year base period plus a two-year option period) indefinite delivery/indefinite quantity contract expands CACI's presence in its C4ISR (command, control, communications, computers, intelligence, surveillance, and reconnaissance) and logistics and material readiness markets. The JPEO-CBD is responsible for advanced research, development, acquisition, fielding, and lifecycle support of chemical and biological detection and reconnaissance systems, protection and decontamination systems, information management systems, medical technology, and installation and force protection systems for DoD missions overseas and in the U.S. To help keep Armed Forces personnel safe from chemical and biological threats, CACI will compete for task orders to provide JPEO-CBD with subject matter experts on chemical and biological defense, the development of technical drawings, configuration management, and logistics analysis and risk management. CACI has extensive C4ISR experience that includes a long history of support on programs such as the U.S. Army's Strategic Services Sourcing (S3) and Technical Engineering Support Services contracts as well as ongoing support of development work for the Army's Stryker Nuclear Biological Chemical Reconnaissance Vehicle.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsContracts
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...